The Lilly Open Innovation Drug Discovery Program
Through the Open Innovation Drug Discovery program (OIDD), Lilly has established a network of top global research talent at academic and biotech institutions to provide them access to proprietary, in vitro phenotypic and target-based assays (PD2 and TargetD2). This partnership is supported by the program’s website portal and application (openinnovation.lilly.com), which lowers the barrier for collaborations between investigators working inside and outside the Lilly walls. Underscoring its success, more than 200 affiliated academic institutions and small biotech companies and thousands of compound samples have been evaluated in the OIDD screening panel, resulting in several collaborations currently ongoing. The OIDD business model rests on the ability to automatically evaluate thousands of virtual structures to select those eligible for biological screening, without any human intervention in order to provide complete protection of the submitter’s intellectual property. This is achieved via the conversion of chemical structures into molecular fingerprints on the secure OIDD web application before their utilization in cheminformatics analyses. For those computations that need to be performed on Lilly internal cheminformatics servers, only these fingerprints – and not the structures themselves – are transferred. As a natural extension of this approach, the OIDD program will now reach out to the global computational chemistry community by introducing a variety of Lilly-developed modeling tools that will provide investigators the option of designing molecules with desirable drug-like properties or suited to a particular biological target. Both SPR and SAR tools will be made available to authorized users via the OIDD application. This presentation will provide a high level description of the OIDD business model, underlying science and progress to date. Additionally, the presenter will further elaborate on the incorporation of modeling and cheminformatics tools (including use of ChemAxon software) and the challenges inherent to providing submitters access to cutting-edge technology via the OIDD website portal. Specific success stories showcasing the results of collaborative efforts with academic partners will also be discussed. A general discussion on lessons learned, issues to be resolved, and future development directions will conclude the presentation.